Solar Stocks Positive; First Solar (NASDAQ:FSLR), On the Move Trading to $45.20
New York, NY - February 17, 2012 - (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in renewable energy stock research for independent investors, issues an investor alert for solar stock First Solar (NASDAQ:FSLR). The stock is currently trading at $42.45, up2.74 (6.90%) 12:50PM EST, with a day’s range of $42.23 - $45.20.
Several solar stocks are up in today's session, following positive news in the sector including fourth quarter results from SunPower Corp. (NASDAQ: SPWR) announced yesterday on the close.
According to the company press release, "We finished the year with a better than expected fourth quarter, as demand for SunPower's differentiated technology sold through our diversified downstream channels enabled us to reach annual records in both revenue and shipments," said Tom Werner, SunPower president and CEO. "Operationally, we achieved both our panel production cost target and accelerated manufacturing step reduction program milestones. Research and development investment results included initial volume production of our Maxeon Gen 3 next generation cell technology with a maximum cell efficiency of 24 percent. As the market transitions, the companies with the strongest balance sheets will gain share. Our strategic partnership with Total SA solidifies SunPower as one of the leading companies in the industry today."
About First Solar, Inc.
First Solar manufactures solar modules with an advanced semiconductor technology, and is a premier provider of comprehensive photovoltaic (PV) system solutions. The company is delivering an economically viable alternative to fossil-fuel generation today. From raw material sourcing through end-of-life collection and recycling, First Solar is focused on creating value-driven renewable energy solutions that protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.
Research more solar stocks on global stock exchanges - and up to 1300 renewable energy stocks at Investorideas.com http://www.investorideas.com/ Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com contact:
800.665.0411
Investor Ideas, stock and news alerts plus podcasts in bitcoin, blockchain, biotech, cannabis, mining, sports, tech stocks and more
Monday, February 20, 2012
Friday, February 17, 2012
Gold and Mining Stocks; Gold Bullion (TSX-V: GBB) Enters Into Option Agreement to Acquire Beaver and Violet Silver Properties, Postpones Castle Silver Mines IPO
VANCOUVER - February 15, 2012 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (TSXV: GBB, OTC PINK: GBBFF) is pleased to announce that it has entered into an option agreement with Ansil Resources Ltd. that gives Gold Bullion the option to acquire 100% ownership of both the Beaver and Violet silver properties located in the township of Coleman, Ontario.
To acquire ownership of both properties, Gold Bullion paid $10,000 to Ansil Resources and over the next seven years must incur an aggregate of $100,000 in expenditures on the properties. Gold Bullion is also required to make annual payments to Ansil Resources for a period of five years in an aggregate amount of $60,000 for pre-payment of a 3% net smelter return royalty held by Ansil Resources. Gold Bullion retains the right to purchase the 3% NSR royalty by paying $1.5 million to Ansil Resources for each percentage point of the NSR royalty.
The Beaver property consists of a single 20-acre claim; the N part, NW1/4, N1/2 Lot 1, Concession III is located in Coleman Township near the town of Cobalt, roughly 80 kilometres southeast of Gold Bullion's Castle Silver Mine near Gowganda, Ontario.
Beaver Consolidated Mines Ltd. produced 221.7 tonnes silver (7,127,858 ounces) from the Beaver Property between 1907 and 1940. The silver was mined from near-vertical Ag-Co-Ni veins near the upper contact of a shallow Nipissing diabase intrusive. This intrusive crosscuts Archean age sedimentary and volcanic rocks.
Production from the mines adjoining the Beaver Mine directly to the South and West were: Temiskaming Mine, 376.9 tonnes silver (12,118,796 ounces), Brady Lake Mine, 96.4 tonnes silver (3,100,000 ounces), Cobalt Load, 139.8 tonnes silver (4,493,725 ounces) and the Christopher Mine, 127.5 tonnes silver (4,100,000 ounces), also in close proximity to the upper contact area of the same Nipissing diabase intrusive.
Between 1977 and 1989 Agnico Eagle Mines produced 124 tonnes silver (3,986,761 ounces) broken down as follows: 122.96 tonnes silver (3,953,319 ounces) from the Cobalt Lode and Duchess claims south of the Beaver property, 0.929 tonnes silver (29,878 ounces) from the Beaver property and 0.111 tonnes silver (3,564 ounces) from the Brady Lake claims. All production was from the lower contact area of the Nipissing diabase. The properties were accessed from the 1,600 foot (487.68 metre) level of the Beaver Shaft and later from a cross cut driven from the Temiskaming Shaft.
Gold Bullion believes that diamond drilling of the lower contact area of the Beaver property is warranted to test a near flat fault known to exist in the Beaver property. A similar flat fault in the Duchess and Cobalt load appears to have been a controlling feature in the ore mined by Agnico Eagle.
Gold Bullion also announces that it has decided to postpone, for market reasons, the previously-announced initial public offering by Castle Silver Mines Inc., and a secondary offering to the shareholders of Gold Bullion of shares of Castle Silver Mines by way of dividend in kind, as set out in Castle Silver Mines' final prospectus dated November 10, 2011.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Quebec.
For more information on Gold Bullion Development Corp. (TSXV:GBB.V) (OTCPINK:GBBFF), visit our web site: : www.GoldBullionDevelopmentCorp.com
The technical information in this release was prepared under the supervision of Mr. Frank J. Basa, P.Eng., Gold Bullion's CEO and President, who is a member of the Ontario Association of Professional Engineers and a "qualified person" in accordance with National Instrument 43-101.
For further information contact:
Frank J. Basa, P.Eng., President and Chief Executive Officer, Tel: (514) 397-4000
Progressive Investor Relations (Canada) Tel (604) 689-2881 or email info@progressive-ir.com
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
VANCOUVER - February 15, 2012 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (TSXV: GBB, OTC PINK: GBBFF) is pleased to announce that it has entered into an option agreement with Ansil Resources Ltd. that gives Gold Bullion the option to acquire 100% ownership of both the Beaver and Violet silver properties located in the township of Coleman, Ontario.
To acquire ownership of both properties, Gold Bullion paid $10,000 to Ansil Resources and over the next seven years must incur an aggregate of $100,000 in expenditures on the properties. Gold Bullion is also required to make annual payments to Ansil Resources for a period of five years in an aggregate amount of $60,000 for pre-payment of a 3% net smelter return royalty held by Ansil Resources. Gold Bullion retains the right to purchase the 3% NSR royalty by paying $1.5 million to Ansil Resources for each percentage point of the NSR royalty.
The Beaver property consists of a single 20-acre claim; the N part, NW1/4, N1/2 Lot 1, Concession III is located in Coleman Township near the town of Cobalt, roughly 80 kilometres southeast of Gold Bullion's Castle Silver Mine near Gowganda, Ontario.
Beaver Consolidated Mines Ltd. produced 221.7 tonnes silver (7,127,858 ounces) from the Beaver Property between 1907 and 1940. The silver was mined from near-vertical Ag-Co-Ni veins near the upper contact of a shallow Nipissing diabase intrusive. This intrusive crosscuts Archean age sedimentary and volcanic rocks.
Production from the mines adjoining the Beaver Mine directly to the South and West were: Temiskaming Mine, 376.9 tonnes silver (12,118,796 ounces), Brady Lake Mine, 96.4 tonnes silver (3,100,000 ounces), Cobalt Load, 139.8 tonnes silver (4,493,725 ounces) and the Christopher Mine, 127.5 tonnes silver (4,100,000 ounces), also in close proximity to the upper contact area of the same Nipissing diabase intrusive.
Between 1977 and 1989 Agnico Eagle Mines produced 124 tonnes silver (3,986,761 ounces) broken down as follows: 122.96 tonnes silver (3,953,319 ounces) from the Cobalt Lode and Duchess claims south of the Beaver property, 0.929 tonnes silver (29,878 ounces) from the Beaver property and 0.111 tonnes silver (3,564 ounces) from the Brady Lake claims. All production was from the lower contact area of the Nipissing diabase. The properties were accessed from the 1,600 foot (487.68 metre) level of the Beaver Shaft and later from a cross cut driven from the Temiskaming Shaft.
Gold Bullion believes that diamond drilling of the lower contact area of the Beaver property is warranted to test a near flat fault known to exist in the Beaver property. A similar flat fault in the Duchess and Cobalt load appears to have been a controlling feature in the ore mined by Agnico Eagle.
Gold Bullion also announces that it has decided to postpone, for market reasons, the previously-announced initial public offering by Castle Silver Mines Inc., and a secondary offering to the shareholders of Gold Bullion of shares of Castle Silver Mines by way of dividend in kind, as set out in Castle Silver Mines' final prospectus dated November 10, 2011.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Quebec.
For more information on Gold Bullion Development Corp. (TSXV:GBB.V) (OTCPINK:GBBFF), visit our web site: : www.GoldBullionDevelopmentCorp.com
The technical information in this release was prepared under the supervision of Mr. Frank J. Basa, P.Eng., Gold Bullion's CEO and President, who is a member of the Ontario Association of Professional Engineers and a "qualified person" in accordance with National Instrument 43-101.
For further information contact:
Frank J. Basa, P.Eng., President and Chief Executive Officer, Tel: (514) 397-4000
Progressive Investor Relations (Canada) Tel (604) 689-2881 or email info@progressive-ir.com
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Disclosure, Disclaimer/ Investorideas.com is paid by GBB to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (five hundred per month)
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Thursday, February 16, 2012
Oil and Gas Services Stock, Profire Energy (OTCBB:PFIE), Reports Record Revenue of $5,068,983 for Third Fiscal Quarter
LINDON, UT and EDMONTON, AB - (Investorideas.com Energy Newswire) - Oil and Gas News - Profire Energy, Inc. (OTC.BB: PFIE) reported net income before income taxes for the quarter ending December 31, 2011 of $1,245,322 on total revenues of $5,068,983. By comparison, during the Company's prior-year third fiscal quarter, it realized net income before income taxes of $846,878 on total revenues of $2,696,417. Earnings per share for the third fiscal quarter 2012 were $.02. Year-over-year revenue and net income growth were 88% and 44%, respectively.
Total revenue for the nine-month period ended December 31, 2011 was $12,275,228 compared to $5,605,063 for the comparable prior year period, a 119% increase. For the same period, net income before income taxes totaled $3,960,607 compared to $1,604,175, a 147% increase. On a per share basis the Company earned $.06 for the nine-month period December 31, 2011, a 200% increase over the nine month period ended December 31, 2010.
"Revenue results for the quarter represent the best ever for the Company. We attribute this to the expansion of our market in the United States, the growth of our sales team and the increase in general activity in energy throughout North America. We have invested heavily in personnel and facilities to accommodate this growth and will continue to do so as we seek to add value through the development and sale of our technologies," stated Andrew Limpert, CFO of Profire Energy, Inc.
About Profire Energy, Inc. (OTC.BB: PFIE)
Profire Energy, Inc. is a leading manufacturer and installer of oilfield combustion management systems and related burner products. Our products and services assist energy production companies in the safe and efficient transportation, refinement and production of oil and natural gas. The Company's lead products are the Profire 2100 and the Profire 1100, which are burner management systems that oil and gas producers rely on to provide reliable management and ignition of combustion burners and associated vessels such as separators, dehydrators, line heaters, incinerators, etc.
To learn more about Profire Energy's products and services, please visit www.profireenergy.com. Profire has offices in Lindon, Utah, U.S.A and Edmonton, Alberta, Canada.
Cautionary Note Regarding Forward-Looking Statements
This release contains "forward-looking" statements regarding our operations, growth of the Company, our investments to expand our capacity, to add value to our products and to develop and sale our technologies. All such forward-looking statements are subject to uncertainty and changes in circumstances. Forward-looking statements are not guarantees of future results or performance and involve risks, assumptions and uncertainties that could cause actual events or results to differ materially from the events or results described in, or anticipated by, the forward-looking statements. Factors that could materially affect such forward-looking statements include economic, business, public market and regulatory risks and factors identified in the Company's periodic reports filed with the Securities Exchange Commission. All forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are made only as of the date of this release and the Company assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements.
Contact:
For inquiries please contact
Andrew Limpert
(801) 796-5127
Published at Investorideas.com Energy Newswire
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: Investorideas.com was compensated 1500 to distribute and publish this press release in email and online at Investorideas.com and its syndicated blogs and news sites.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
LINDON, UT and EDMONTON, AB - (Investorideas.com Energy Newswire) - Oil and Gas News - Profire Energy, Inc. (OTC.BB: PFIE) reported net income before income taxes for the quarter ending December 31, 2011 of $1,245,322 on total revenues of $5,068,983. By comparison, during the Company's prior-year third fiscal quarter, it realized net income before income taxes of $846,878 on total revenues of $2,696,417. Earnings per share for the third fiscal quarter 2012 were $.02. Year-over-year revenue and net income growth were 88% and 44%, respectively.
Total revenue for the nine-month period ended December 31, 2011 was $12,275,228 compared to $5,605,063 for the comparable prior year period, a 119% increase. For the same period, net income before income taxes totaled $3,960,607 compared to $1,604,175, a 147% increase. On a per share basis the Company earned $.06 for the nine-month period December 31, 2011, a 200% increase over the nine month period ended December 31, 2010.
"Revenue results for the quarter represent the best ever for the Company. We attribute this to the expansion of our market in the United States, the growth of our sales team and the increase in general activity in energy throughout North America. We have invested heavily in personnel and facilities to accommodate this growth and will continue to do so as we seek to add value through the development and sale of our technologies," stated Andrew Limpert, CFO of Profire Energy, Inc.
About Profire Energy, Inc. (OTC.BB: PFIE)
Profire Energy, Inc. is a leading manufacturer and installer of oilfield combustion management systems and related burner products. Our products and services assist energy production companies in the safe and efficient transportation, refinement and production of oil and natural gas. The Company's lead products are the Profire 2100 and the Profire 1100, which are burner management systems that oil and gas producers rely on to provide reliable management and ignition of combustion burners and associated vessels such as separators, dehydrators, line heaters, incinerators, etc.
To learn more about Profire Energy's products and services, please visit www.profireenergy.com. Profire has offices in Lindon, Utah, U.S.A and Edmonton, Alberta, Canada.
Cautionary Note Regarding Forward-Looking Statements
This release contains "forward-looking" statements regarding our operations, growth of the Company, our investments to expand our capacity, to add value to our products and to develop and sale our technologies. All such forward-looking statements are subject to uncertainty and changes in circumstances. Forward-looking statements are not guarantees of future results or performance and involve risks, assumptions and uncertainties that could cause actual events or results to differ materially from the events or results described in, or anticipated by, the forward-looking statements. Factors that could materially affect such forward-looking statements include economic, business, public market and regulatory risks and factors identified in the Company's periodic reports filed with the Securities Exchange Commission. All forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are made only as of the date of this release and the Company assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements.
Contact:
For inquiries please contact
Andrew Limpert
(801) 796-5127
Published at Investorideas.com Energy Newswire
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: Investorideas.com was compensated 1500 to distribute and publish this press release in email and online at Investorideas.com and its syndicated blogs and news sites.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Nanotechnology Stocks; mPhase Technologies (OTC.BB:XDSL) Strengthening Patent Portfolio
LITTLE FALLS, NJ - February 14, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) said today that it has been developing intellectual property based on an innovative platform technology to control the flow of fluids by electronically manipulating the way liquids behave when in contact with a solid or porous surface.
The Company has a patent portfolio in Smart Surfaces of 11 patent applications consisting of a combination of solely owned, jointly owned and patents licensed with its development partners covering the mPhase Smart NanoBattery and its Smart Surface Technology.
The Company is beginning to strengthen its patent portfolio beyond batteries. Future application filings will concentrate in the commercial and consumer areas targeting medical and portable electronic applications.
To date mPhase has focused its development of this innovative technology platform for advanced battery applications. The mPhase Smart NanoBattery has a unique architecture that enables a shelf life of decades, remote activation, programmable control and adaptability to multiple chemistries within the same container. These attributes lend themselves to creative applications outside of batteries.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.
LITTLE FALLS, NJ - February 14, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) said today that it has been developing intellectual property based on an innovative platform technology to control the flow of fluids by electronically manipulating the way liquids behave when in contact with a solid or porous surface.
The Company has a patent portfolio in Smart Surfaces of 11 patent applications consisting of a combination of solely owned, jointly owned and patents licensed with its development partners covering the mPhase Smart NanoBattery and its Smart Surface Technology.
The Company is beginning to strengthen its patent portfolio beyond batteries. Future application filings will concentrate in the commercial and consumer areas targeting medical and portable electronic applications.
To date mPhase has focused its development of this innovative technology platform for advanced battery applications. The mPhase Smart NanoBattery has a unique architecture that enables a shelf life of decades, remote activation, programmable control and adaptability to multiple chemistries within the same container. These attributes lend themselves to creative applications outside of batteries.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.
Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.
Nanotechnology Stocks; mPhase Technologies, Inc. (OTC.BB:XDSL) in Continuing Negotiations With Private Equity Group
LITTLE FALLS, NJ - February 13, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) announced today that it is in continuing negotiations with a Private Equity group to invest capital in the Company that would exceed its current capitalized value in the public equity markets. The Private Equity investment would accelerate the ability of the Company to market its products including its new automotive and marine product soon to be announced. Such an investment would enable the Company to significantly increase its current value and would involve an innovative structure designed to maximize value for present and future shareholders of the Company. As previously announced such an investment would enable the Company to avoid continuous financings in the public markets, thereby eliminating the potentially dilutive effect on the Company's shares. The Company believes that its goal of initial and continuing profitability based upon its products and intellectual property would be accelerated. Such acceleration of revenues in the consumer products area would supplement the Company's continued pursuit to receive government funding for its SmartNanoBattery and other products related to its Smart Surface Technology.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.
LITTLE FALLS, NJ - February 13, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) announced today that it is in continuing negotiations with a Private Equity group to invest capital in the Company that would exceed its current capitalized value in the public equity markets. The Private Equity investment would accelerate the ability of the Company to market its products including its new automotive and marine product soon to be announced. Such an investment would enable the Company to significantly increase its current value and would involve an innovative structure designed to maximize value for present and future shareholders of the Company. As previously announced such an investment would enable the Company to avoid continuous financings in the public markets, thereby eliminating the potentially dilutive effect on the Company's shares. The Company believes that its goal of initial and continuing profitability based upon its products and intellectual property would be accelerated. Such acceleration of revenues in the consumer products area would supplement the Company's continued pursuit to receive government funding for its SmartNanoBattery and other products related to its Smart Surface Technology.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.
Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.
Medical Technology Stock Alert; PositiveID (OTCBB:PSID) Achieves Positive Preliminary Results From Diabetes Research Institute Study at the University of Miami
DELRAY BEACH, Fla. - February 13, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), a developer of medical technologies for diabetes management, announced today positive preliminary results from its biotransport research study with the Diabetes Research Institute ("DRI") at the University of Miami relating to PositiveID's GlucoChip(TM). GlucoChip is a glucose-sensing implantable microchip, currently under development with partner RECEPTORS LLC, for individuals with diabetes. Preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids.
PositiveID's first animal studies were designed to test the membrane materials that will be the interface between the glucose sensing device and the in vivo environment by evaluating the ability of glucose to pass through the membrane to the sensing device (glucose transport).
Robert E. Carlson, Ph.D., President and Chief Scientific Officer of RECEPTORS, said, "These first studies were successfully completed with the demonstration that a glucose tracer readily enters the device from surrounding body fluids. We are currently implementing the next phase of these studies, which will focus in more detail on both the kinetics of transport, which will determine how quickly the device will be able to respond to changes in glucose levels in the body, and on the long-term biocompatibility of the membrane."
PositiveID Chairman and CEO William J. Caragol said, "We believe the preliminary results from our research study at the DRI are not only positive but also promising as we proceed with our development. By achieving early confirmation that the membrane materials we will use with GlucoChip allow for movement of glucose from fluids in the body into the glucose-sensing device, we have begun to eliminate one of the significant hurdles of this potentially ground-breaking development project."
PositiveID and RECEPTORS LLC have completed prototype development of a stable and reproducible, closed-cycle continuous glucose-sensing system, which is the mission-critical component of GlucoChip. Continued positive results from the biocompatibility and biotransport study would position PositiveID to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip.
GlucoChip is based on the PositiveID's Patent No. 7,125,382 for an "Embedded Bio-Sensor System." The Embedded Bio-Sensor System patent covers a bio-sensor system that utilizes radio frequency identification technology and includes a remote transponder in wireless communication with an implantable, passively-powered, on-chip transponder. PositiveID now has five patents and patents pending surrounding the development of GlucoChip.
More than 25 million children and adults in the U.S. have diabetes, or over 8 percent of the population, according to the 2011 National Diabetes Fact Sheet. The CDC predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. The lifetime risk of developing diabetes for those born in the year 2000 is 35 percent. The total cost of diagnosed diabetes in the U.S. is estimated at $200 billion.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the likelihood that preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids; the likelihood that these first studies were successfully completed with the demonstration that a glucose tracer readily enters the device from surrounding body fluids; the likelihood that the next phase of these studies, which will focus in more detail on both the kinetics of transport, will determine how quickly the device will be able to respond to changes in glucose levels in the body, and on the long-term biocompatibility of the membrane; the likelihood that the preliminary results from PositiveID's research study at the DRI are not only positive but also promising as the company proceeds with its development; the likelihood that by achieving early confirmation that the membrane materials PositiveID will use with GlucoChip allow for movement of glucose from fluids in the body into the glucose-sensing device, the company has begun to eliminate one of the significant hurdles of this exciting development project; the likelihood that the prototype development of a stable and reproducible, closed-cycle continuous glucose-sensing system is the mission-critical component of GlucoChip; the likelihood that continued positive results from the biocompatibility and biotransport study would position the company to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip; the likelihood that nearly 30 percent of children born after the year 2000 will develop diabetes; the likelihood that the lifetime risk of developing diabetes for those born in the year 2000 is 35 percent; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully complete this research study of the membrane materials to be used in GlucoChip of Easy Check; PositiveID's ability to complete development of and commercialize GlucoChip; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
DELRAY BEACH, Fla. - February 13, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), a developer of medical technologies for diabetes management, announced today positive preliminary results from its biotransport research study with the Diabetes Research Institute ("DRI") at the University of Miami relating to PositiveID's GlucoChip(TM). GlucoChip is a glucose-sensing implantable microchip, currently under development with partner RECEPTORS LLC, for individuals with diabetes. Preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids.
PositiveID's first animal studies were designed to test the membrane materials that will be the interface between the glucose sensing device and the in vivo environment by evaluating the ability of glucose to pass through the membrane to the sensing device (glucose transport).
Robert E. Carlson, Ph.D., President and Chief Scientific Officer of RECEPTORS, said, "These first studies were successfully completed with the demonstration that a glucose tracer readily enters the device from surrounding body fluids. We are currently implementing the next phase of these studies, which will focus in more detail on both the kinetics of transport, which will determine how quickly the device will be able to respond to changes in glucose levels in the body, and on the long-term biocompatibility of the membrane."
PositiveID Chairman and CEO William J. Caragol said, "We believe the preliminary results from our research study at the DRI are not only positive but also promising as we proceed with our development. By achieving early confirmation that the membrane materials we will use with GlucoChip allow for movement of glucose from fluids in the body into the glucose-sensing device, we have begun to eliminate one of the significant hurdles of this potentially ground-breaking development project."
PositiveID and RECEPTORS LLC have completed prototype development of a stable and reproducible, closed-cycle continuous glucose-sensing system, which is the mission-critical component of GlucoChip. Continued positive results from the biocompatibility and biotransport study would position PositiveID to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip.
GlucoChip is based on the PositiveID's Patent No. 7,125,382 for an "Embedded Bio-Sensor System." The Embedded Bio-Sensor System patent covers a bio-sensor system that utilizes radio frequency identification technology and includes a remote transponder in wireless communication with an implantable, passively-powered, on-chip transponder. PositiveID now has five patents and patents pending surrounding the development of GlucoChip.
More than 25 million children and adults in the U.S. have diabetes, or over 8 percent of the population, according to the 2011 National Diabetes Fact Sheet. The CDC predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. The lifetime risk of developing diabetes for those born in the year 2000 is 35 percent. The total cost of diagnosed diabetes in the U.S. is estimated at $200 billion.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the likelihood that preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids; the likelihood that these first studies were successfully completed with the demonstration that a glucose tracer readily enters the device from surrounding body fluids; the likelihood that the next phase of these studies, which will focus in more detail on both the kinetics of transport, will determine how quickly the device will be able to respond to changes in glucose levels in the body, and on the long-term biocompatibility of the membrane; the likelihood that the preliminary results from PositiveID's research study at the DRI are not only positive but also promising as the company proceeds with its development; the likelihood that by achieving early confirmation that the membrane materials PositiveID will use with GlucoChip allow for movement of glucose from fluids in the body into the glucose-sensing device, the company has begun to eliminate one of the significant hurdles of this exciting development project; the likelihood that the prototype development of a stable and reproducible, closed-cycle continuous glucose-sensing system is the mission-critical component of GlucoChip; the likelihood that continued positive results from the biocompatibility and biotransport study would position the company to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip; the likelihood that nearly 30 percent of children born after the year 2000 will develop diabetes; the likelihood that the lifetime risk of developing diabetes for those born in the year 2000 is 35 percent; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully complete this research study of the membrane materials to be used in GlucoChip of Easy Check; PositiveID's ability to complete development of and commercialize GlucoChip; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.aspVisit the company profile: http://www.investorideas.com/CO/PSID/
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Chairman and CEO of PositiveID (OTCBB: PSID) Discusses Catalysts for 2012 in Diabetes Market and Homeland Security Market
New York, NY- February 16, 2012 – (Investorideas.com Newswire) Medical Technology Stock news alert: Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Medical technology stock, PositiveID Corporation (OTCBB: PSID). Mr. William J. Caragol, Chairman and Chief Executive Officer discusses the catalysts for 2012 for both its diabetes management technologies and its Homeland Security airborne bio-threat detection technology.
Q: Investorideas.com
We noted that late last year the Department of Homeland Security (“DHS”) Office of Health Affairs began the procurement process for the deployment of an autonomous biodetection system called BioWatch Gen-3. Can you give investors insight as to the potential 2012 opportunities for the Company’s airborne bio-threat detection technology (M-BAND) in this process?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Our MicroFluidic Systems (“MFS”) subsidiary, is a leader in biothreat detection technologies and molecular diagnostic systems, and developed its M-BAND technology under contract from DHS over the past eight years. We believe our M-BAND, a Microfluidics-based Bioagent Autonomous Networked Detector, is one of only two technologies that is compatible with DHS’ procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years, as described by the DHS in their draft RFP. This opportunity, relative to the provision of biodetectors and the renewables, represents a very significant opportunity for PositiveID.
Q: Investorideas.com
With your three diabetes management technologies, Easy Check™, GlucoChip™ and iglucose™, can you give investors a quick summary of some of the recent key developments announced by the Company and some of the key drivers for 2012?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We continue to make significant progress with each of our diabetes management products. Starting with Easy Check, our non-invasive breath glucose detection device, we completed a prototype device in 2011 and achieved positive preliminary results in early testing that are within industry standards. We recently announced the initiation of a clinical study of Easy Check with Schneider Children’s Medical Center in Israel, led by a world leading endocrinologist. We expect to have results from that study later this year.
Moving on to GlucoChip, a continuous glucose-sensing microchip, we have completed Phase II development and proved a stable and reproducible, closed-cycle continuous glucose sensor that functions in human blood. We also recently provided an update on a biotransport study we are conducting with the Diabetes Research Institute at the University of Miami, which has yielded positive preliminary results. We will continue to provide updates on our progress over the next few months. As those results develop, we will look to work with a partner to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip
Last but not least, we received FDA clearance for iglucose, which is a mobile health system for diabetes management, in late 2011, and are now preparing to roll-out this product with health insurers and home-healthcare providers. As we look ahead to the rest of 2012, we expect that the initial roll-out of iglucose in the first half of the year will be followed by larger orders and partnering agreements.
Q: Investorideas.com
Your technology takes management of diabetes to the clouds literally. With the iglucose technology, the data stored in the diabetes management portal can be shared automatically by text messaging or email. How significant a breakthrough is this for family members, caregivers and healthcare professionals and most importantly, the patient?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
The value proposition of iglucose is to provide an individual with diabetes flexibility and wireless connectivity to better manage their condition and stay in touch with loved ones. With iglucose, an individual no longer has to keep manual logbooks – iglucose automatically pulls the data from a glucometer and sends it to the cloud. Patients can continue to use their preferred blood glucose meter and there is no cell phone or data plan required. iglucose simplifies diabetes management by automating the process of providing blood glucose readings to healthcare professionals for more informed communication and treatment decisions. iglucose also provides peace of mind for family members that their loved ones are testing and what their values are.
Q: Investorideas.com
Easy Check is your non-invasive breath glucose detection device that measures the level of acetone in a patient's exhaled breath and correlates that acetone level to a measure of blood glucose. With a rapid growth of diabetes in children how significant is it to have a technology that could eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Being able to provide the diabetes community with a non-invasive method of testing their blood sugar is often called the “Holy Grail” of diabetes management. Certainly for children, offering non-invasive testing is even more important and appealing. Many times, people with diabetes do not test as often as prescribed by their physician due to the pain and inconvenience of drawing blood.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that its M-BAND is one of only two technologies that is compatible with DHS’ procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years, as described by the DHS in their draft RFP; the likelihood that this opportunity, relative to the provision of biodetectors and the renewables, represents a very significant opportunity for PositiveID; the likelihood that PositiveID will continue to make significant progress with each of its diabetes management products; the likelihood that PositiveID will have results from its Easy Check clinical study later this year; the likelihood that PositiveID will continue to provide updates on its progress with GlucoChip over the next few months; the likelihood that as those results develop, PositiveID will look to work with a partner to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip; the likelihood that PositiveID is now preparing to roll-out this product with health insurers and home-healthcare providers; the likelihood that the initial roll-out of iglucose in the first half of the year will be followed by larger orders and partnering agreements; the likelihood that iglucose simplifies diabetes management by automating the process of providing blood glucose readings to healthcare professionals for more informed communication and treatment decisions; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully complete development and commercialize Easy Check, GlucoChip and iglucose; the likelihood that PositiveID will participate in BioWatch Gen-3; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Learn more about PSID at Investorideas.com
http://www.investorideas.com/CO/PSID/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30, 2012. Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile .More info:www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact Investorideas.com 800 665 0411
New York, NY- February 16, 2012 – (Investorideas.com Newswire) Medical Technology Stock news alert: Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Medical technology stock, PositiveID Corporation (OTCBB: PSID). Mr. William J. Caragol, Chairman and Chief Executive Officer discusses the catalysts for 2012 for both its diabetes management technologies and its Homeland Security airborne bio-threat detection technology.
Q: Investorideas.com
We noted that late last year the Department of Homeland Security (“DHS”) Office of Health Affairs began the procurement process for the deployment of an autonomous biodetection system called BioWatch Gen-3. Can you give investors insight as to the potential 2012 opportunities for the Company’s airborne bio-threat detection technology (M-BAND) in this process?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Our MicroFluidic Systems (“MFS”) subsidiary, is a leader in biothreat detection technologies and molecular diagnostic systems, and developed its M-BAND technology under contract from DHS over the past eight years. We believe our M-BAND, a Microfluidics-based Bioagent Autonomous Networked Detector, is one of only two technologies that is compatible with DHS’ procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years, as described by the DHS in their draft RFP. This opportunity, relative to the provision of biodetectors and the renewables, represents a very significant opportunity for PositiveID.
Q: Investorideas.com
With your three diabetes management technologies, Easy Check™, GlucoChip™ and iglucose™, can you give investors a quick summary of some of the recent key developments announced by the Company and some of the key drivers for 2012?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We continue to make significant progress with each of our diabetes management products. Starting with Easy Check, our non-invasive breath glucose detection device, we completed a prototype device in 2011 and achieved positive preliminary results in early testing that are within industry standards. We recently announced the initiation of a clinical study of Easy Check with Schneider Children’s Medical Center in Israel, led by a world leading endocrinologist. We expect to have results from that study later this year.
Moving on to GlucoChip, a continuous glucose-sensing microchip, we have completed Phase II development and proved a stable and reproducible, closed-cycle continuous glucose sensor that functions in human blood. We also recently provided an update on a biotransport study we are conducting with the Diabetes Research Institute at the University of Miami, which has yielded positive preliminary results. We will continue to provide updates on our progress over the next few months. As those results develop, we will look to work with a partner to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip
Last but not least, we received FDA clearance for iglucose, which is a mobile health system for diabetes management, in late 2011, and are now preparing to roll-out this product with health insurers and home-healthcare providers. As we look ahead to the rest of 2012, we expect that the initial roll-out of iglucose in the first half of the year will be followed by larger orders and partnering agreements.
Q: Investorideas.com
Your technology takes management of diabetes to the clouds literally. With the iglucose technology, the data stored in the diabetes management portal can be shared automatically by text messaging or email. How significant a breakthrough is this for family members, caregivers and healthcare professionals and most importantly, the patient?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
The value proposition of iglucose is to provide an individual with diabetes flexibility and wireless connectivity to better manage their condition and stay in touch with loved ones. With iglucose, an individual no longer has to keep manual logbooks – iglucose automatically pulls the data from a glucometer and sends it to the cloud. Patients can continue to use their preferred blood glucose meter and there is no cell phone or data plan required. iglucose simplifies diabetes management by automating the process of providing blood glucose readings to healthcare professionals for more informed communication and treatment decisions. iglucose also provides peace of mind for family members that their loved ones are testing and what their values are.
Q: Investorideas.com
Easy Check is your non-invasive breath glucose detection device that measures the level of acetone in a patient's exhaled breath and correlates that acetone level to a measure of blood glucose. With a rapid growth of diabetes in children how significant is it to have a technology that could eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Being able to provide the diabetes community with a non-invasive method of testing their blood sugar is often called the “Holy Grail” of diabetes management. Certainly for children, offering non-invasive testing is even more important and appealing. Many times, people with diabetes do not test as often as prescribed by their physician due to the pain and inconvenience of drawing blood.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that its M-BAND is one of only two technologies that is compatible with DHS’ procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years, as described by the DHS in their draft RFP; the likelihood that this opportunity, relative to the provision of biodetectors and the renewables, represents a very significant opportunity for PositiveID; the likelihood that PositiveID will continue to make significant progress with each of its diabetes management products; the likelihood that PositiveID will have results from its Easy Check clinical study later this year; the likelihood that PositiveID will continue to provide updates on its progress with GlucoChip over the next few months; the likelihood that as those results develop, PositiveID will look to work with a partner to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip; the likelihood that PositiveID is now preparing to roll-out this product with health insurers and home-healthcare providers; the likelihood that the initial roll-out of iglucose in the first half of the year will be followed by larger orders and partnering agreements; the likelihood that iglucose simplifies diabetes management by automating the process of providing blood glucose readings to healthcare professionals for more informed communication and treatment decisions; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully complete development and commercialize Easy Check, GlucoChip and iglucose; the likelihood that PositiveID will participate in BioWatch Gen-3; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Learn more about PSID at Investorideas.com
http://www.investorideas.com/CO/PSID/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30, 2012. Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile .More info:www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact Investorideas.com 800 665 0411
Wednesday, February 15, 2012
Oil and Gas Services Stock, Profire Energy ( OTCBB:PFIE), Reports Record Revenue of $5,068,983 for Third Fiscal Quarter
Company Reports Nine Month Revenue Increase of 119%
LINDON, UT and EDMONTON, AB--(Investorideas.com Energy Newswire )- Oil and Gas News -Profire Energy, Inc. (OTC.BB: PFIE) reported net income before income taxes for the quarter ending December 31, 2011 of $1,245,322 on total revenues of $5,068,983. By comparison, during the Company's prior-year third fiscal quarter, it realized net income before income taxes of $846,878 on total revenues of $2,696,417. Earnings per share for the third fiscal quarter 2012 were $.02. Year-over-year revenue and net income growth were 88% and 44%, respectively.
Total revenue for the nine-month period ended December 31, 2011 was $12,275,228 compared to $5,605,063 for the comparable prior year period, a 119% increase. For the same period, net income before income taxes totaled $3,960,607 compared to $1,604,175, a 147% increase. On a per share basis the Company earned $.06 for the nine-month period December 31, 2011, a 200% increase over the nine month period ended December 31, 2010.
"Revenue results for the quarter represent the best ever for the Company. We attribute this to the expansion of our market in the United States, the growth of our sales team and the increase in general activity in energy throughout North America. We have invested heavily in personnel and facilities to accommodate this growth and will continue to do so as we seek to add value through the development and sale of our technologies," stated Andrew Limpert, CFO of Profire Energy, Inc.
About Profire Energy, Inc. (OTC.BB: PFIE)
Profire Energy, Inc. is a leading manufacturer and installer of oilfield combustion management systems and related burner products. Our products and services assist energy production companies in the safe and efficient transportation, refinement and production of oil and natural gas. The Company's lead products are the Profire 2100 and the Profire 1100, which are burner management systems that oil and gas producers rely on to provide reliable management and ignition of combustion burners and associated vessels such as separators, dehydrators, line heaters, incinerators, etc.
To learn more about Profire Energy's products and services, please visit www.profireenergy.com. Profire has offices in Lindon, Utah, U.S.A and Edmonton, Alberta, Canada.
Cautionary Note Regarding Forward-Looking Statements
This release contains "forward-looking" statements regarding our operations, growth of the Company, our investments to expand our capacity, to add value to our products and to develop and sale our technologies. All such forward-looking statements are subject to uncertainty and changes in circumstances. Forward-looking statements are not guarantees of future results or performance and involve risks, assumptions and uncertainties that could cause actual events or results to differ materially from the events or results described in, or anticipated by, the forward-looking statements. Factors that could materially affect such forward-looking statements include economic, business, public market and regulatory risks and factors identified in the Company's periodic reports filed with the Securities Exchange Commission. All forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are made only as of the date of this release and the Company assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements.
Contact:
.
For inquiries please contact
Andrew Limpert
(801) 796-5127
E-mail: Email Contact
Published at Investorideas.com Energy Newswire
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: Investorideas.com was compensated 1500 to distribute and publish this press release in email and online at Investorideas.com and its syndicated blogs and news sites.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Company Reports Nine Month Revenue Increase of 119%
LINDON, UT and EDMONTON, AB--(Investorideas.com Energy Newswire )- Oil and Gas News -Profire Energy, Inc. (OTC.BB: PFIE) reported net income before income taxes for the quarter ending December 31, 2011 of $1,245,322 on total revenues of $5,068,983. By comparison, during the Company's prior-year third fiscal quarter, it realized net income before income taxes of $846,878 on total revenues of $2,696,417. Earnings per share for the third fiscal quarter 2012 were $.02. Year-over-year revenue and net income growth were 88% and 44%, respectively.
Total revenue for the nine-month period ended December 31, 2011 was $12,275,228 compared to $5,605,063 for the comparable prior year period, a 119% increase. For the same period, net income before income taxes totaled $3,960,607 compared to $1,604,175, a 147% increase. On a per share basis the Company earned $.06 for the nine-month period December 31, 2011, a 200% increase over the nine month period ended December 31, 2010.
"Revenue results for the quarter represent the best ever for the Company. We attribute this to the expansion of our market in the United States, the growth of our sales team and the increase in general activity in energy throughout North America. We have invested heavily in personnel and facilities to accommodate this growth and will continue to do so as we seek to add value through the development and sale of our technologies," stated Andrew Limpert, CFO of Profire Energy, Inc.
About Profire Energy, Inc. (OTC.BB: PFIE)
Profire Energy, Inc. is a leading manufacturer and installer of oilfield combustion management systems and related burner products. Our products and services assist energy production companies in the safe and efficient transportation, refinement and production of oil and natural gas. The Company's lead products are the Profire 2100 and the Profire 1100, which are burner management systems that oil and gas producers rely on to provide reliable management and ignition of combustion burners and associated vessels such as separators, dehydrators, line heaters, incinerators, etc.
To learn more about Profire Energy's products and services, please visit www.profireenergy.com. Profire has offices in Lindon, Utah, U.S.A and Edmonton, Alberta, Canada.
Cautionary Note Regarding Forward-Looking Statements
This release contains "forward-looking" statements regarding our operations, growth of the Company, our investments to expand our capacity, to add value to our products and to develop and sale our technologies. All such forward-looking statements are subject to uncertainty and changes in circumstances. Forward-looking statements are not guarantees of future results or performance and involve risks, assumptions and uncertainties that could cause actual events or results to differ materially from the events or results described in, or anticipated by, the forward-looking statements. Factors that could materially affect such forward-looking statements include economic, business, public market and regulatory risks and factors identified in the Company's periodic reports filed with the Securities Exchange Commission. All forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are made only as of the date of this release and the Company assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements.
Contact:
.
For inquiries please contact
Andrew Limpert
(801) 796-5127
E-mail: Email Contact
Published at Investorideas.com Energy Newswire
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: Investorideas.com was compensated 1500 to distribute and publish this press release in email and online at Investorideas.com and its syndicated blogs and news sites.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Sunday, February 12, 2012
Social Networking Stock Alert: LinkedIn (NYSE:LNKD) Trades Up on Fourth Quarter News
New York, New York - February 10, 2012 - www.InvestorIdeas.com, a global investor research portal, specializing in sector research including tech stocks issues an investor alert for social networking and media stock, LinkedIn Corporation (NYSE:LNKD). The stock is trading up at $84.64 8.25(10.80%) 10:10AM EST, with a morning high of $86.10. The Company reported its financial results for the fourth quarter and fiscal year ended December 31, 2011 on the close yesterday.
Summary of Results
About LinkedIn (NYSE:LNKD)
Founded in 2003, LinkedIn connects the world's professionals to make them more productive and successful. With more than 150 million members worldwide, including executives from every Fortune 500 company, LinkedIn is the world's largest professional network on the Internet. The company has a diversified business model with revenues coming from member subscriptions, marketing solutions and hiring solutions. Headquartered in Silicon Valley, LinkedIn has offices across the globe.
Research Social Networking/ Social Media Stocks:
Visit the Investorideas.com Social Networking Stocks Directory preview page:
http://www.investorideas.com/ TSS/Social_Networking_Stocks.asp
Become an Investor Ideas Member Today - Get 24/7 access to our exclusive members only - 13 stock directories; energy, renewable energy, mining stocks, water, biotech. Added bonus for members - New Tech Stocks Directory for Social Networking and Cloud Computing Stocks
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/ Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Source - Investorideas.com
800-665-0411 - dawn@investorideas.com
New York, New York - February 10, 2012 - www.InvestorIdeas.com, a global investor research portal, specializing in sector research including tech stocks issues an investor alert for social networking and media stock, LinkedIn Corporation (NYSE:LNKD). The stock is trading up at $84.64 8.25(10.80%) 10:10AM EST, with a morning high of $86.10. The Company reported its financial results for the fourth quarter and fiscal year ended December 31, 2011 on the close yesterday.
Summary of Results
- Revenue for the fourth quarter was $167.7 million, an increase of 105% compared to $81.7 million for the fourth quarter of 2010
- Net income for the fourth quarter was $6.9 million, compared to net income of $5.3 million for the fourth quarter of 2010; Non-GAAP net income for the fourth quarter was $13.3 million, compared to $5.2 million for the fourth quarter of 2010. Non-GAAP measures exclude tax-affected stock-based compensation expense and tax-affected amortization of acquired intangible assets
- Adjusted EBITDA for the fourth quarter was $34.4 million, or 21% of revenue, compared to $16.3 million for the fourth quarter of 2010, or 20% of revenue
- GAAP EPS for the fourth quarter was $0.06; Non-GAAP EPS for the fourth quarter was $0.12
- For the full year 2011, revenue increased 115% to $522.2 million from $243.1 million. GAAP EPS increased to $0.11 from $0.07 and Non-GAAP EPS increased to $0.35 from $0.24. Adjusted EBITDA increased to $98.7 million from $48.0 million
About LinkedIn (NYSE:LNKD)
Founded in 2003, LinkedIn connects the world's professionals to make them more productive and successful. With more than 150 million members worldwide, including executives from every Fortune 500 company, LinkedIn is the world's largest professional network on the Internet. The company has a diversified business model with revenues coming from member subscriptions, marketing solutions and hiring solutions. Headquartered in Silicon Valley, LinkedIn has offices across the globe.
Research Social Networking/ Social Media Stocks:
Visit the Investorideas.com Social Networking Stocks Directory preview page:
http://www.investorideas.com/ TSS/Social_Networking_Stocks.asp
Become an Investor Ideas Member Today - Get 24/7 access to our exclusive members only - 13 stock directories; energy, renewable energy, mining stocks, water, biotech. Added bonus for members - New Tech Stocks Directory for Social Networking and Cloud Computing Stocks
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/ Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Source - Investorideas.com
800-665-0411 - dawn@investorideas.com
Nanotechnology Stocks; mPhase Technologies, Inc. (OTC.BB:XDSL) to File Drug Delivery Patent
LITTLE FALLS, NJ - February 10, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) said today that it intends to file a patent based on its Smart Surface technology for a novel drug delivery system.
The drug delivery patent is based on the ability of mPhase's Smart Surface technology to electronically control the precise flow of a fluid on a nano-structured surface.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.
LITTLE FALLS, NJ - February 10, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) said today that it intends to file a patent based on its Smart Surface technology for a novel drug delivery system.
The drug delivery patent is based on the ability of mPhase's Smart Surface technology to electronically control the precise flow of a fluid on a nano-structured surface.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.
Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.
Friday, February 10, 2012
Solar News: GM (NYSE:GM) China Headquarters Installs Sunlogics (18L1:GR) GreenZone® Solar Charging Station
SHANGHAI, China - February 9, 2012 (Investorideas.com renewable energy newswire) General Motors (NYSE:GM) China has completed the installation of the first Sunlogics (18L1:GR) GreenZone® Solar Charging Station at its Shanghai headquarters. Sunlogics, a GM Ventures equity partner, created the GreenZone to be installed at GM's various facilities and dealerships around the world to support the introduction of the Chevrolet Volt extended-range electric vehicle and prepare for future EV vehicle programs. The GreenZone® provides a unique opportunity to charge electric vehicles using a pure renewable energy source, the sun.
"The installation of the GreenZone solar charging station at our GM China headquarters proves our commitment to help develop an electric vehicle charging infrastructure in the Chinese market," said Ray Bierzynski, executive director of electrification strategy for GM China. "GM will continue to play a vital role working with major infrastructure suppliers and electrical utilities to provide convenient, reliable charging solutions for our EV owners now and well into the future."
The GreenZone®Solar Charging Station installed at GM's China headquarters has a rated power output of 10 kW, which is enough to fully recharge up to six Chevrolet Volts each day. The GreenZone installation was completed by China Triumph International Engineering Company, the Sunlogics' Engineering, Procurement and Construction contractor for GM projects.
General Motors and Sunlogics signed a Master Agreement on July 28, 2011, outlining a $7.5 million equity investment in Sunlogics PLC by General Motors Ventures LLC, giving Sunlogics the ability to develop the GreenZoneSolar Charging Station and larger scale commercial solar projects.
"The Sunlogics GreenZone®Solar Charging Station captures energy from the sun and transforms it into clean, green renewable power, which is added to the grid, offsetting electricity used to charge electric vehicles. The GM China Shanghai installation is the first of its kind in China," says Charles Bryant, Sunlogics Interim Chief Executive Officer.
About General Motors (NYSE:GM)
General Motors traces its roots back to 1908. GM has 11 joint ventures, two wholly owned foreign enterprises and more than 35,000 employees in China . GM and its joint ventures offer the broadest lineup of vehicles and brands among automakers in China . Passenger cars and commercial vehicles are sold under the Baojun, Buick, Cadillac, Chevrolet, Jiefang, Opel and Wuling brands. In 2011, GM sold 2.55 million vehicles in China , which represented 8.3 percent growth over the prior year. It has been the sales leader among global automakers in the market for six consecutive years. More information on General Motors in China can be found at GM Media Online.
About Sunlogics (18L1:GR)
Sunlogics PLC is a vertically integrated global solar energy systems provider specializing in solar project development and installation. The scope of the company's operations includes Canada , United States , Europe and China . More information can be found at www.sunlogics.com.
Kevin M. Kelly
GM China Communications
Kevin.M.Kelly@GM.com
86 138 1705 1956
Jessica Feng
GM China Communications
Jessica.Feng@GM.com
021-28987520
Franklin Santagate
Sunlogics PLC
Franklin@sunlogics.com
623-986-1947 (Cell)
Disclaimer
The following information is intended for investors who are able to thoroughly evaluate and accept potential risks related to an investment in shares issued by this company. This information neither presents an offer to sell nor an invitation to buy or subscribe for shares of this company.
The shares of this company are neither admitted to trading on the Regulated Market nor included in trading on the Regulated Market. They are included in trading in the Open Market (Regulated Unofficial Market) of FWB Frankfurter Wertpapierb�rse (the Frankfurt Stock Exchange). Investors must be aware of the fact that the Open Market (Regulated Unofficial Market) on the Frankfurt Stock Exchange is not subject to the high Europe-wide transparency standards and strict provisions for investor protection on EU-regulated markets.
US-Disclaimer
The following web pages are not intended for persons resident in the United States of America , the United Kingdom , Canada , Japan or any country other than Germany . The content of these web pages does not constitute an invitation to buy securities in the United States of America , the United Kingdom , Canada , Japan or any other country than Germany . The securities specified herein are not and will not be registered in the United States of America in accordance with the current valid edition of the U.S. Securities Act of 1933
SHANGHAI, China - February 9, 2012 (Investorideas.com renewable energy newswire) General Motors (NYSE:GM) China has completed the installation of the first Sunlogics (18L1:GR) GreenZone® Solar Charging Station at its Shanghai headquarters. Sunlogics, a GM Ventures equity partner, created the GreenZone to be installed at GM's various facilities and dealerships around the world to support the introduction of the Chevrolet Volt extended-range electric vehicle and prepare for future EV vehicle programs. The GreenZone® provides a unique opportunity to charge electric vehicles using a pure renewable energy source, the sun.
"The installation of the GreenZone solar charging station at our GM China headquarters proves our commitment to help develop an electric vehicle charging infrastructure in the Chinese market," said Ray Bierzynski, executive director of electrification strategy for GM China. "GM will continue to play a vital role working with major infrastructure suppliers and electrical utilities to provide convenient, reliable charging solutions for our EV owners now and well into the future."
The GreenZone®Solar Charging Station installed at GM's China headquarters has a rated power output of 10 kW, which is enough to fully recharge up to six Chevrolet Volts each day. The GreenZone installation was completed by China Triumph International Engineering Company, the Sunlogics' Engineering, Procurement and Construction contractor for GM projects.
General Motors and Sunlogics signed a Master Agreement on July 28, 2011, outlining a $7.5 million equity investment in Sunlogics PLC by General Motors Ventures LLC, giving Sunlogics the ability to develop the GreenZoneSolar Charging Station and larger scale commercial solar projects.
"The Sunlogics GreenZone®Solar Charging Station captures energy from the sun and transforms it into clean, green renewable power, which is added to the grid, offsetting electricity used to charge electric vehicles. The GM China Shanghai installation is the first of its kind in China," says Charles Bryant, Sunlogics Interim Chief Executive Officer.
About General Motors (NYSE:GM)
General Motors traces its roots back to 1908. GM has 11 joint ventures, two wholly owned foreign enterprises and more than 35,000 employees in China . GM and its joint ventures offer the broadest lineup of vehicles and brands among automakers in China . Passenger cars and commercial vehicles are sold under the Baojun, Buick, Cadillac, Chevrolet, Jiefang, Opel and Wuling brands. In 2011, GM sold 2.55 million vehicles in China , which represented 8.3 percent growth over the prior year. It has been the sales leader among global automakers in the market for six consecutive years. More information on General Motors in China can be found at GM Media Online.
About Sunlogics (18L1:GR)
Sunlogics PLC is a vertically integrated global solar energy systems provider specializing in solar project development and installation. The scope of the company's operations includes Canada , United States , Europe and China . More information can be found at www.sunlogics.com.
Kevin M. Kelly
GM China Communications
Kevin.M.Kelly@GM.com
86 138 1705 1956
Jessica Feng
GM China Communications
Jessica.Feng@GM.com
021-28987520
Franklin Santagate
Sunlogics PLC
Franklin@sunlogics.com
623-986-1947 (Cell)
Disclaimer
The following information is intended for investors who are able to thoroughly evaluate and accept potential risks related to an investment in shares issued by this company. This information neither presents an offer to sell nor an invitation to buy or subscribe for shares of this company.
The shares of this company are neither admitted to trading on the Regulated Market nor included in trading on the Regulated Market. They are included in trading in the Open Market (Regulated Unofficial Market) of FWB Frankfurter Wertpapierb�rse (the Frankfurt Stock Exchange). Investors must be aware of the fact that the Open Market (Regulated Unofficial Market) on the Frankfurt Stock Exchange is not subject to the high Europe-wide transparency standards and strict provisions for investor protection on EU-regulated markets.
US-Disclaimer
The following web pages are not intended for persons resident in the United States of America , the United Kingdom , Canada , Japan or any country other than Germany . The content of these web pages does not constitute an invitation to buy securities in the United States of America , the United Kingdom , Canada , Japan or any other country than Germany . The securities specified herein are not and will not be registered in the United States of America in accordance with the current valid edition of the U.S. Securities Act of 1933
Nanotechnology Stocks; mPhase Technologies, Inc. (OTC.BB:XDSL) in Negotiations With Private Equity Group
LITTLE FALLS, NJ - February 9, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) announced today that it is in negotiations with a Private Equity group to invest a minimum of $2 million in mPhase. The Private Equity investment would enable the Company to avoid continuous financings in the public markets and would also bring a new Board Member to the Company with a solid foundation in cost reduction and marketing. This would accelerate the time to market for the Company's products. The acceleration to market in the consumer products area would supplement the Company's continued pursuit to receive government funding for its SmartNanoBattery and other products related to its Smart Surface Technology.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.
LITTLE FALLS, NJ - February 9, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) announced today that it is in negotiations with a Private Equity group to invest a minimum of $2 million in mPhase. The Private Equity investment would enable the Company to avoid continuous financings in the public markets and would also bring a new Board Member to the Company with a solid foundation in cost reduction and marketing. This would accelerate the time to market for the Company's products. The acceleration to market in the consumer products area would supplement the Company's continued pursuit to receive government funding for its SmartNanoBattery and other products related to its Smart Surface Technology.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.
Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.
Thursday, February 09, 2012
Biotech stocks News; BioSante Pharmaceuticals (NasdaqGM: BPAX) Reports Positive LibiGel® Safety Data Review for Phase III Program
LINCOLNSHIRE, Ill. - February 9, 2012 (Investorideas.com Newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel (testosterone gel) is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women.
BioSante reported that with 3,656 women enrolled and over 5,800 women-years of exposure in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 31 adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately 0.53 percent. In the same population of subjects, there have been 19 breast cancers reported, a rate of approximately 0.33 percent, which is in line with the ages of the subjects enrolled in the study.
"The DMC once again has recommended that the safety study continue as per the FDA-agreed protocol, without modification, as there were no general or specific safety issues based on their unblinded review of adverse events. We are pleased with the low number of CV events to date and we believe it is consistent with the safety of testosterone in this population," stated Michael Snabes, M.D., Ph.D., the senior vice president of medical affairs for BioSante.
Subjects have been enrolled in this study for an average of 19.3 months. More than 2,500 subjects have been enrolled in the study for more than a year and over 830 subjects have been enrolled for more than two years. The periodic reviews by the DMC are based on their mandate in accordance with FDA agreement on protocol-defined study oversight.
"BioSante's LibiGel Phase III safety study continues," said Stephen M. Simes, BioSante president & chief executive officer. "We plan to meet with the FDA to determine the best path forward for the program, and will make a decision as to the conduct of the LibiGel safety study during the second quarter of this year. We have instituted appropriate cost savings in order to minimize the continuing cost of the safety study. Although LibiGel did not meet the co-primary or secondary endpoints in two Phase III efficacy studies, BioSante continues to investigate alternative strategies to utilize the continuing LibiGel cardiovascular event and breast cancer safety study."
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 subjects. The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including, for example, hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
About LibiGel
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). BioSante continues to analyze the LibiGel data from the two pivotal Phase III efficacy trials first reported on December 14, 2011. These trials were double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy. Initial analysis of the efficacy data from these trials shows that the trials did not meet the co-primary or secondary endpoints. Although there were no statistical differences from placebo, results indicated that LibiGel performed as predicted based on previous experience with testosterone products for FSD. Unfortunately, the placebo response in the two efficacy trials was overwhelming; and therefore, LibiGel's results were not shown to be statistically different from placebo. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase I and Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to its products and the LibiGel development program, including in particular the LibiGel safety study and the anticipated timing of BioSante's decision whether to continue the safety study, BioSante's future burn rate and cash runway and other statements identified by words such as "will," "continue," "could," "believes," "intends," "expects," "anticipates," "plans," "may," "potential," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, additional analyses of data from the LibiGel efficacy trials and any other LibiGel clinical trials, including the safety study, may be inconsistent with previously announced results or previously conducted clinical trials or may produce negative or inconclusive results; there may be varying interpretations of data produced by clinical trials; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success of clinical testing, the success of BioSante's licensees or sublicensees and BioSante's future revenues, if any, from its licensees and sublicensees; uncertainties relating to the future and costs of BioSante's product development programs, its future burn rate and its need for and ability to obtain additional financing if needed. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release and are based on BioSante's current beliefs and expectations. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary
312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other stocks http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: Investorideas.com is paid by BPAX to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (six thousand five hundred per three months of publishing)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
LINCOLNSHIRE, Ill. - February 9, 2012 (Investorideas.com Newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel (testosterone gel) is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women.
BioSante reported that with 3,656 women enrolled and over 5,800 women-years of exposure in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 31 adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately 0.53 percent. In the same population of subjects, there have been 19 breast cancers reported, a rate of approximately 0.33 percent, which is in line with the ages of the subjects enrolled in the study.
"The DMC once again has recommended that the safety study continue as per the FDA-agreed protocol, without modification, as there were no general or specific safety issues based on their unblinded review of adverse events. We are pleased with the low number of CV events to date and we believe it is consistent with the safety of testosterone in this population," stated Michael Snabes, M.D., Ph.D., the senior vice president of medical affairs for BioSante.
Subjects have been enrolled in this study for an average of 19.3 months. More than 2,500 subjects have been enrolled in the study for more than a year and over 830 subjects have been enrolled for more than two years. The periodic reviews by the DMC are based on their mandate in accordance with FDA agreement on protocol-defined study oversight.
"BioSante's LibiGel Phase III safety study continues," said Stephen M. Simes, BioSante president & chief executive officer. "We plan to meet with the FDA to determine the best path forward for the program, and will make a decision as to the conduct of the LibiGel safety study during the second quarter of this year. We have instituted appropriate cost savings in order to minimize the continuing cost of the safety study. Although LibiGel did not meet the co-primary or secondary endpoints in two Phase III efficacy studies, BioSante continues to investigate alternative strategies to utilize the continuing LibiGel cardiovascular event and breast cancer safety study."
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 subjects. The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including, for example, hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
About LibiGel
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). BioSante continues to analyze the LibiGel data from the two pivotal Phase III efficacy trials first reported on December 14, 2011. These trials were double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy. Initial analysis of the efficacy data from these trials shows that the trials did not meet the co-primary or secondary endpoints. Although there were no statistical differences from placebo, results indicated that LibiGel performed as predicted based on previous experience with testosterone products for FSD. Unfortunately, the placebo response in the two efficacy trials was overwhelming; and therefore, LibiGel's results were not shown to be statistically different from placebo. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase I and Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to its products and the LibiGel development program, including in particular the LibiGel safety study and the anticipated timing of BioSante's decision whether to continue the safety study, BioSante's future burn rate and cash runway and other statements identified by words such as "will," "continue," "could," "believes," "intends," "expects," "anticipates," "plans," "may," "potential," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, additional analyses of data from the LibiGel efficacy trials and any other LibiGel clinical trials, including the safety study, may be inconsistent with previously announced results or previously conducted clinical trials or may produce negative or inconclusive results; there may be varying interpretations of data produced by clinical trials; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success of clinical testing, the success of BioSante's licensees or sublicensees and BioSante's future revenues, if any, from its licensees and sublicensees; uncertainties relating to the future and costs of BioSante's product development programs, its future burn rate and its need for and ability to obtain additional financing if needed. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release and are based on BioSante's current beliefs and expectations. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary
312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other stocks http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: Investorideas.com is paid by BPAX to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (six thousand five hundred per three months of publishing)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
More Info:
This news is published on the Investorideas.com Newswire and its syndicated partner network
Subscribe to:
Posts (Atom)